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g.2014.0Abstract For many inherited diseases, the same mutation is not always expressed in all persons
who carry it, moreover, when the mutation is expressed, it is not always expressed in the same
way. These findings are the basis for the concepts of penetrance and expressivity. Understanding
the factors that control penetrance of disease genes will provide insight into the fundamental disease
processes and will help in genetic counselling.
With the advancement of molecular genetics over the last few years, some of the underlying
mechanisms of reduced penetrance have been elucidated. These include, mutation type, allelic
variations in gene expression, epigenetic factors, gene-environment interplay, influence of age and
sex, allele dosage, oligogenic and digenic inheritance mutations, modifier genes, copy number
variations as well as the influence of additional gene variants and the effect of single nucleotide
polymorphisms.
The aim of this review is to clarify factors affecting gene penetrance as well as some of the
underlying molecular mechanisms in some genetic disorders.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.Contents
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Penetrance is defined as the percentage of individuals having a
particular mutation or genotype who exhibit clinical signs or
phenotype of the associated disorder or genotype [1].
Complete penetrance indicates that individuals who have
the disease – causing mutation have clinical symptoms of the
disease e.g. familial adenomatous polyposis, multiple endo-
crine neoplasia and retinoblastoma. Incomplete or reduced
penetrance indicates that some individuals fail to express the
trait, even though they carry the allele e.g. incomplete pene-
trance of the dominant mutations in the LMNA gene of Emery
Dreifuss muscular dystrophy [2]. Low penetrance allele indi-
cates that this allele will only sometimes produce the symptoms
at a detectable level e.g. low penetrance of retinoblastoma for
p. V654L mutation of RBI gene [3]. Pseudo-incomplete
penetrance indicates that the observation of non penetrance
is inaccurate because the clinical examination is incomplete
or the symptoms have not yet appeared at the time of the
examination. It is also seen in germ line mosaicism that is only
seen in the first generation when the parents of several affected
children with a dominant disease are healthy [3].
Variable expressivity on the other hand means the extent to
which a genotype is phenotypically expressed in individuals.
Individuals with a certain mutation can exhibit differences in
disease severity, even among members of the same family.
Examples of diseases that display a range of phenotypes in-
clude neurofibromatosis, holoprosencephaly [4] and genetic
syndromes [5–8].
Healthy individuals can harbour large number of poten-
tially or mildly disadvantageous variants and perhaps tens of
potentially severe disease alleles without suffering any obvious
ill effects [9]. These variants may damage the protein in ques-
tion, but the intact protein may not be necessary for the health
of the carrier. The individual may be an asymptomatic carrier
of a single recessive mutant allele or the mutation is dominant,
but the clinical phenotype might be only mild and lying within
the range of normal healthy variations or become apparent in
later decades of life [1].
Each individual was found to carry 281–515 missense sub-
stitutions predicted with a high degree of confidence to be
damaging to the gene product, 40–85 of which were present
in the homozygous state. Taken together these studies suggest
that a typical healthy individual has about 80 of their genes
severely damaged or inactivated in both copies, further empha-
sising the stark contrast between damage to gene and protein
on one hand and damage to health on the other hand [1].
Until recently reduced penetrance is a term used exclusively
for autosomal dominant disorders. However the existence of
healthy homozygotes of autosomal recessive disorders has beendemonstrated by molecular analysis [10]. Irrespective of the
mode of inheritance penetrance is likely to be a function of
the specific mutation(s) involved. Examples of reduced pene-
trance in autosomal dominant disorders include, congenital
cataract (GJA3 gene) [11], different types of retinitis pigmen-
tosa (PRPF8 & PRPF31) [12], and long QT syndrome [13].
Examples of autosomal recessive disorders include Cys 282tyr
(rs1800562), mutation in hemochromatosis gene (HFE) [14],
and GBA mutations, (Asn 409ser, rs76763715) in deafness [15].
Reduced penetrance being a widespread phenomenon in
human genetics as evidenced from next generation sequencing
of entire exomes or genomes of apparently healthy individuals
represents a major challenge to genetic counsellors in quantify-
ing the disease risk to the patient’s offspring [16]. Also it
complicates the recognition of heritable basis of heritable
diseases [17], as well as blurring the distinction between mono-
genic conditions and complex diseases. [18].
2. Factors affecting penetrance
2.1. Mutation type and penetrance
Incomplete penetrance may be due to the effect of the type of
mutation. Some mutations of a given disease may exhibit com-
plete penetrance, where as others in the same gene show
incomplete or very low penetrance. e.g. the penetrance of the
common mutation for cystic fibrosis, CFTR (D Phe 508,
rs113993960) is very high, while the penetrance of CFTR
Arg 117 His (rs78655421) mutation is very low, so as to suggest
its withdrawal from cystic fibrosis mutation panel used for
screening programmes [19].
Reduced penetrance in some genetic disorders may also
depend on genetic background of gene carriers. InHirschsprung
disease (HSCR), although the presence ofRETmutations is suf-
ficient to explain HSCR inheritance, a genome scan reveals that
new susceptibility locus on 9q-31 is also required to cause the
disease [20].
Reduced penetrance may also be due to the type of muta-
tion. Splice site mutations in RBI gene of retinoblastoma lead
to reduced penetrance, due to reduction in the amount of Rb
protein produced [21]. Null mutations on the other hand tend
to exhibit lower penetrance than missense and splicing muta-
tions as in Col3A1. Null mutation reduces the amount of
normal collagen produced, while the other mutations produce
faulty gene product which disrupt the entire helical collagen
molecule [22]. Patients harbouring missense mutations in
BMPR2 gene exhibit early and severe pulmonary hypertension
than patients harbouring truncating mutations [23]. Double
missense mutations may lead to incomplete penetrance in cis
as in fabry disease, as one of the two mutations may represent
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clinical penetrance of one mutation may be strongly influenced
by the nature of the other mutation in trans. Thus two non-
sense/truncating mutations in GJB2 gene produce more severe
deafness than two missense mutations [24].
Location of the mutation may also affect penetrance. Thus
mutation in cysteine residue of the TNFRSF1A gene causing
TNF receptor associated periodic syndrome is more penetrant
that mutation in the non-cysteine residue [25].
Penetrance may also be incomplete in compound heterozy-
gotes as in MEFV gene mutations responsible for familial
Mediterranean fever [26].
In diseases which exhibit locus heterogeneity clinical pene-
trance may vary between mutations in different genes as in
deafness [24]. Reduced penetrance may also be characteristic
of many triplet repeat expansion disorders as in Huntington
disease. The possession of intragenic (HTT) CAG repeats of
36–39 copies is often associated with reduced penetrance and
later age of onset of clinical symptoms [27].
2.2. Variation in gene expression and penetrance
Humans are characterised by marked inter-individual varia-
tion in levels of expression of their genes even in members of
the same family which can influence the penetrance of
pathological mutations [28]. This may be due to differential
contribution of mutant alleles to the clinical profile i.e. allelic
heterogeneity as in familial Mediterranean fever, (MEFV
gene). M694V homozygotes have a severe form of the disease,
while mutations in E148Q and V726A have reduced pene-
trance [29].
Cis and Trans-acting factors also control gene expression.
Cis-acting elements are DNA sequences in the vicinity of the
structural portion of a gene that is required for gene
expression. Trans-acting factors are considered to be proteins,
that bind to the cis-acting sequences to control gene expres-
sion. Difference in gene expression may be mediated through
polymorphism in any of them (cis acting elements). Differen-
tial expression of wild and mutant alleles can also affect
penetrance, e.g. unequal allelic expression of the wild type
(MYH7-mRNA) and mutated B-myosin transcript and
proteins in familial hypertrophic cardiomyopathy. This is
characteristic for each mutation, implying cis-acting regulatory
mechanisms. [30].
Different degrees of expression in different individuals may
also be due to variation in allelic constitution of the rest of the
genome or to environmental factors. [31].
Genome sequencing studies indicate that humans carry
many genetic variants predicted to cause loss of function
(LoF) of protein-coding genes, suggesting redundancy in the
human genome. They estimated that human genomes typically
contain 100 genuine LoF variants with 20 genes completely
inactivated. About 26 rare and likely deleterious LoF variants
were identified as well as 21 severe disease–causing variants
and common LoF variants in nonessential genes [32].
2.3. Epigenetic changes and penetrance
Epigenetic changes or modifications indicate the sum of
heritable changes, such as DNA methylation, histone modifi-
cation and miRNA expression as well as environmental andstochastic factors which can affect gene expression and re-
duced penetrance without changing the DNA sequence [33].
Epigenetic variations have been suggested to have an impor-
tant role in cellular senescence, tumorigenesis and in several
diseases including type 2- diabetes, cardiovascular, autoim-
mune diseases, obesity and Alzheimer’s disease. A correlation
between epigenetic DNA modifications and human life span
has also been shown by Fraga et al. [34] who found that global
and local-specific differences in DNA methylation in identical
twins of different ages are influenced by environmental factors
and lifestyle.
Most studies demonstrated that aging is associated with a
relaxation in epigenetic control, due to a decrease in global
cystosine methylation mostly in transportable repetitive
elements [35].
Epigenetic modifications in the pathophysiology of neuro-
degenerative diseases with consequent transcriptional dysregu-
lation might be an important marker of disease status and its
progression [36]. Epigenetic allele silencing may also play a
role in malignant hyperthermia susceptibility [37].
Epigenetic modification may also account for a specific
disease phenotype in twins and in terms of an epigenotype as
they are discordant for childhood leukaemia because they have
discordant BRCA1 methylation status [38].
A special case of imprinting is provided by X-inactivation,
when a disease gene is X-linked. Shewed X-inactivation can
cause variable penetrance of pathogenic mutations in female
carriers e.g. the EBP gene (XP11.23) in X-linked dominant
chondrodysplasia punctata [39].
Genes can also affect one’s risk of obesity. However there
are several epigenetic influences that alter the expression of
our genes and ultimately our risk of becoming obese. Failure
of epigenetic markers or imprinting can affect gene expression
and cause extreme forms of obesity (e.g. Prader–willi
syndrome). [40].
2.4. Gene-Environment interplay and penetrance
The environment will often influence clinical penetrance, either
ameliorating or exacerbating the impact of heritable genetic
variants. Environmental modifiers of disease penetrance in-
clude sex, diet, drugs, alcohol intake, metabolic syndromes
and physical activity [41].
In phenylketonuria (PKU), newborns found to have high
levels of phenylalanine in their blood can be put on a special
low phenylalanine diet to avoid severe effects of PKU. Thus
diet can act as an important modifier of clinical penetrance
[42].
An inherited predisposition to obesity in carriers of
PPARG2 Pro 12A Ala alelle can be modified by low fat intake
[43]. The risk of obesity can also be attenuated in persons
having genetic variants at the FTO locus by physical activity
[44]. Women appear to be more responsive to environmental
risk factors causing multiple sclerosis [45].
The most evident environmental influence on penetrance
is in cancer susceptibility. Traditionally gene-environment
interactions are thought to contribute to tumour suppressor –
gene penetrance by facilitating or inhibiting the acquisition
of additional somatic mutations required for tumorigenesis.
Exposure to environmental factors (diethylstilbestrol) during
development can permanently reprogram normal physiologi-
106 R.M. Shawkycal tissue responses and this leads to increased tumour–
suppressor gene penetrance in genetically susceptible
individuals [46].
There is an association between heritable genetic varia-
tions at the nicotinic acetylcholine receptor (CHRNA5/
CHRNA3/CHRNB4) locus on chromosome 15q 25.1 and
lung cancer. Allele T of SNP rs1051730 a synonymous vari-
ant located within exon 5 of CHRNA3 gene was found to
be strongly associated with smoking quantity, whether this
effect is direct or indirect [47]. The risk of lung cancer con-
ferred directly or indirectly by genetic variants on 15q 25
would be small if the individual concerned simply opted
not to smoke [48].
Persons who were abused as children and have a genotype
conferring high levels of functional polymorphism in the
monoamine oxidase A (MAOA) gene promotor which pro-
duces high levels of MAO are less likely to develop symptoms
of antisocial behavior [49].
2.5. Increasing age and penetrance
The clinical symptoms of some disease mutations are
increasingly likely to manifest themselves with increasing
age of risk individuals, e.g. MYBPC3 in hypertrophic cardio-
myopathy [50], Emery-Dreifuss muscular dystrophy [2] and
familial obesity due to melanocortin-4-receiptor deficiency
[51].
The most common genetic cause of familial and sporadic
amyotrophic lateral silerosis (ALS) and frontotemporal
dementia (FTD) is a massive GGGGCC hexanucleotide intro-
nic repeat expansion mutation within C9 or F72. The mean age
of onset was 57.9 years for ALS cases and 63.6 years for FTD.
Age dependent penetrance rose steeply from 9% at 50 years to
70% by 70 years and 74% by 85 years. Penetrance was not
influenced by sex of the proband and was similar for parents
and siblings of the probands. However a significantly earlier
age of onset was seen in offspring compared to their parents
with a mean difference of 6.9 years [52].
Risk of both breast and ovarian cancer is consistently
estimated to be higher in BRCA1 than in BRCA2 mutation
carriers. The estimated cumulative risks of breast cancer by
age 70 years were 55–56% for BRCA1 and 45–47% for
BRCA2 mutation carriers. Ovarian cancer risks were 39%
for BRCA1 and 1–17% for BRCA2 mutation carriers [53].
Even different BRCA1 gene mutations have distinct effects
that influence the age of onset of breast or ovarian cancer.
The 185 delAG mutation of the BRCA1 gene is a low
penetrance mutation that is age dependent especially when
compared with the exon 13 duplication mutations. The median
age of affliction with breast cancer was 55 years for 185 delAG
in exon 2, 47 years for the 4184 del TCAA mutation in exon 11
and 41 years for exon 13 duplication [54].
In some cases, the clinical penetrance of a particular muta-
tion can change quite dramatically with age. The cumulative
incidence among carriers of the Arg 1441 Gly mutation in
the LRRK2 gene causing Parkinson disease was found to be
12.5% until the age of 65 years, but 83% until age 80 [55].
However the penetrance of TTR Val 30 Met mutation caus-
ing autosomal dominant familial amyloid polyneuropathy has
been estimated to be 1.7% until the age of 30 years, 22% until
the age of 60 but still only 69% until age 90 [56].2.6. Effect of sex on penetrance
Sex influenced disorders are disorders that demonstrate gender–
related penetrance or the phenotype expression is more likely to
occur in a specific gender. The effect of sex on penetrance of
inheritedmutationswas found in a variety of heritable disorders.
In cases of hereditary breast/ovarian cancer caused by BRCA2
mutation, about 6% of males as opposed to 86% of females
are expected to develop breast cancer by age 70 [57].
The penetrance and attack frequency of hypokalemic peri-
odic paralysis (Hypo PP) due to SCNA4 mutation were lower
in females than in males. Males had 100% penetrance and
50–150 attacks/year, compared to 28.27% penetrance and
30–50 attacks/year in females and the attacks disappear during
pregnancy. This is most probably due to the effect of estrogens
[58].
Sex limited disorders refer to autosomal disorders that are
nonpenetrant for a particular gender. Male limited precocious
puberty is one example. Males heterozygous for mutations in
LCGR gene located in chromosome 2 exhibit this phenotype,
but females with the same genotype do not [57].
Allelic variation may also influence the clinical phenotype
in a sex specific fashion. The KCNE1 Asp 85 Asn
(rs1805128) polymorphism was associated with a Q-T interval
prolongation in males but not female type 1 long QT syndrome
patients harbouring KCNO1 Gly 589 Asp mutation [1].
Parent of origin effect (Genomic imprinting) was evident in
SGCE mutation in myoclonic dystonia. Maternal imprinting
ensures that the pathologically effective mutations are almost
invariably inherited from the father [59]. There is increased risk
for breast cancer in the leaner women especially in the post-
menopeusal group, related to the TEXB–alpha. The pesticides
aldrin and lindane are also individually associated risk [60]. It
is likely that the underlying mechanism is differential gene reg-
ulation in males and females particularly in relation to sex ste-
roid–responsive genes [61].
2.7. Allele number and penetrance
The term autosomal dominant implies that the homozygotes
exhibit the same or a similar clinical phenotype to the hetero-
zygotes. However in practice, for most dominant human
disorders the clinical symptoms in homozygotes tend to be sig-
nificantly more severe than in the heterozygotes [62]. This is
true in low-penetrance mutations e.g. mutations in the RET
gene, associated with isolated Hirschsprung disease (HSCR)
which are dominant loss-of-function mutations with incom-
plete penetrance and variable expressivity. Although the
heterozygous IVS + 5G- > A mutation is of low penetrance
for short segment HSCR, the homozygous state is fully pene-
trant for total agangliosis or long segment HSCR. Thus the
penetrance of RET gene mutations in HSCR depends not only
on the nature of the mutation but also on the allele dosage as
well as the modifier [63].
Variants of the melanocortin 1 receptor (MC1R) gene are
common in individuals with red hair and fair skin, but the rel-
ative contribution to these pigmentary traits in heterozygotes,
homozygotes and compound heterozygotes for variants at this
locus from the multiple alleles present in Caucasian popula-
tions is unclear. The shade of red hair frequently differs in
heterozygotes from that in homozygotes/compound heterozy-
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beard hair colour, skin type and freckling. These data provide
evidence for a dosage effect of MC1R variants on hair as well
as skin colour [64].
A linear relationship between AGT235T allele number (‘‘dos-
age’’) and blood pressure in an ethnically mixed urban popula-
tion confirmed its role as an independent risk factor for
hypertension for men and women when in homozygosity [65].
2.8. Oligogenic inheritance and penetrance
Incomplete penetrance of a mutation can be due to the
oligogenic nature of the disease and hence to requirement for
multiple genes to be mutated for the condition to manifest [1].
Oligogenic inheritance may occur in cases of nephronoph-
thisis. Nephronophthisis (NPHP) is a recessive cystic renal dis-
ease that leads to end stage renal failure. Twenty-five percent
of nephronophthisis cases are caused by large homozygous
deletions of NPHP1, but six genes responsible for nephron-
ophthisis have been identified. Two mutations in one of
NPHP1–4 genes were identified in 44 families with NPHP.
Furthermore digenic disease was detected in one patient who
carried one mutation in NPHP2 and a second mutation in
NPHP4. Also a single mutation was detected in nine families
suggesting that the second mutation may be another as yet
unidentified NPHP gene [66].
Oligogenic inheritance can also be demonstrated in the Hir-
schsprung disease (HSCR). Long segment, L-HSCR, sometimes
syndromic, is caused by coding sequence mutations at one of
several loci including RET, GDNF, SOX10, EDN3 and
EDNRB [67,68]. Short segment S-HSCR (80% of cases) reveals
complex segregation patterns involving contribution from at
least three loci, one of which is the RET gene on chromosome
10q11 with a multiplicative interaction with other loci at 3p21
and 19q12, encompassing currently unidentified gene [68].
Other examples of monogenic inheritance include Holo-
prosencephaly [69], Bardet–Biedle syndrome [70], sporadic
epilepsy [71] familial venous thrombosis [72].
2.9. Digenic inheritance and penetrance
Digenic inheritance occurs in cases where the interaction of
mutations in two different genes is required for expression of
clinical phenotype. In this situation, a mutation in one copy
of each gene is required for full clinical phenotype. The double
heterozygous probands exhibit a more severe phenotype than
his single heterozygous relative i.e. complete penetrance [73].
In the absence of one of the mutations, the other mutation
may be non penetrance or could be responsible for a less severe
phenotype or reduced penetrance [1,73] e.gs of digenic inheri-
tance, include Bardet–Biedle syndrome, Q-T syndrome,
hypogonadotrophic hypogonadism, nephrotic syndrome and
holoprosencephaly.
In hypogonadotrophic hypogonadism(IHH) a significant
inter- and intrafamilial variability and apparent incomplete
penetrance in familial cases are present. Two different gene de-
fects (FGFR1 and NELF) synergize to produce a more severe
phenotype in IHH families (Kallmann syndrome, IHH and
anosmia) than either alone [74].
The Bardet–Biedle syndrome is an autosomal recessive dis-
order where four genes have been identified, BBS1, BBS2,BBS4 and BBS6. The potential requirement for a third muta-
tion in a second BBS gene in addition to two mutations in the
first BBS gene was termed ‘‘triallelic’’ [75].
Digenic inheritance may also occur as a result of mutations
in the genes encoding different subunits of the same multimeric
protein (e.g. PRpH2 & ROM1), an oligomeric complex
(KCNJ 10 & SLC26A4) or simply two proteins may directly
interact with each other to form a structural component (e.g.
polycystins 1&2). However mutations in receptor/ligand pairs
can also result in digenic inheritance (e.g. PROK2 & PRO-
KR2). Digenic inheritance can involve mutations in different
genes that compromise the regulatory (e.g. HFE & HAMP),
biosynthetic (e.g. ZMPSTE 2484 & LMNA) or degradative
pathways (e.g. PC5 kg & LDLR pathway). The two proteins
may be in the same signalling pathway, but act at distinct steps
e.g. a ligand could induce the activity of a transcriptional fac-
tor [1].
In practice it is not always clear if a given situation consti-
tutes a true digenic inheritance [76] or it is simply the co-inher-
itance of two mutations in different genes. In the former case –
the expression of disease phenotype requires the presence of
both gene lesions. In the latter case, co-inheritance may aggra-
vate the clinical phenotype, but each lesion is associated with
its own clinical sequelae [77].
2.10. Modifier genes and penetrance
In single gene disorders there is one gene which is primarily
responsible for the disease with one or more independently
located inherited modifier genes that influence the phenotype
[1]. So any genes involved in the pathogenic process or play
a role in phenotypic variation or altered disease severity repre-
sent modifier genes [78].
Variants in unlinked modifier genes which affect penetrance
have been reported in many diseases including, pancreatitis
[79], Gaucher disease [61], and cardiomyopathy [80].
Many different gene loci, have been reported to be responsi-
ble for non syndromic autosomal recessive hearing loss. In a
large pedigree, linkage to the chromosomal region 4q31 was
demonstrated [81]. Also homozygosity of DFNB 26 gene was
found in all affected individuals as well as in many unaffected
individuals andZlotogorawas able to demonstrate the existence
of a dominant modifier (DFNM1) on chromosome 1q24 [10].
In cystic fibrosis, it is not possible to predict the clinical
phenotype of a patient based solely on knowledge of the exact
mutation in the cystic fibrosis gene, CFTR. In fact at least se-
ven different modifier genes have been described that alter the
clinical phenotype [82]. Although numerous environmental
factors have been identified as influencing cystic fibrosis (CF)
pulmonary phenotype, there is now growing evidence that
polymorphic variants in genes beside CFTR play an important
role in determining severity of CF lung disease [83]. These
modifier gene include MBL2-O (variant alleles of MBL2 gene)
which produces mannose binding lectin (MBL), functional
polymorphisms in TGFB1 gene in both promoter (509)
and at position +869 (codon 10) which influence circulating
levels of transforming growth factor B, [84] a1, antitrypsin
(SERPINA1), [85] B2 adrenergic receptor (ADRB2), [86]
Glutathione S-transferase (GSTM1) [87], Nitric oxide synthase
(NOS3) [88], Tumour necrosis factor (TNF), and Glutamate-
cysteine ligase (GCLC) [89].
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gene influences the risk of renal amyloidosis (RA) in patients
with familial Mediterranean fever (FMF), a Mendalian autoin-
flammatory disorder associated with mutations in MEFV
gene. Indeed the SAA1 and homozygous genotype at the
MEFV locus are two main risk factors for RA [90].
2.11. Copy number variations and penetrance
Genomic copy number variations (CNVS) are increasingly
recognised to contribute to risk for human diseases. CNV
involving loss (e.g. deletions) or gain (e.g. duplication) of up to
several million base pairs of DNA sequence constitute upward
of 5% of human genome. CNV can alter gene dosage and may
involve multiple genes and/or regulatory regions. In general
CNVdeletions showhigher penetrance (more severe phenotype)
than duplications and longer CNVs often have higher pene-
trance and/or more clinical features than smaller CNVs [91].
Estimates of clinical penetrance of recurrent pathogenic
copy number variations (CNV) vary widely depending upon
CNV size, genomic location, disorder in question and genetic
variants in vicinity [92].
There is evidence for disease penetrance relating to CNV
size in the Pelizaeus Merzbacher disease (characterised by leuc-
odystrophy in which myelin is not formed in CNS) and man-
ifesting carriers with a familial 11 Mb duplication at Xq22
genomic region, including proteolipid protein (PLP1) [93].
Also Mintz demonstrated that CNVs are 19% more common
in autism that in controls [94].
Male-biased autosomal effect of 16p13.11CNVwas reported
in neurodevelopmental disorders including autism, ADHD,
intellectual disability and schizophrenia. Associated analysis re-
vealed an excess of CNV in cases compared with controls and a
sex biased effect, with a significant enrichment of CNVs only in
the male subgroup of cases and not in females [95].
Recent observation in human indicates a tentative link be-
tween CNV and weight regulation. Smith-Magenis syndrome
(SMS) manifesting obesity and hypercholesterolemia results
from deletion CNV at 17p11.2, but is sometimes due to hap-
loinsufficiency of a single gene, RAI1. The reciprocal duplica-
tion in 17p11.2 causes Potocki–Lupski syndrome (PTLS).
Lacria et al., demonstrated that Dp(11)17 is obesity apposing.
It conveys a highly penetrant, strain independent phenotype of
reduced weight, linear body composition, lower TC/LDL and
insulin sensitivity that is not due to alteration in food intake or
activity level in mice and men [96].
There is synergy between multiple large CNVs leading to
severe intellectual disability and congenital anomalies [97].
CNV can ameliorate clinical phenotype in spinal muscular
atrophy where an increased copy number of SMN2 gene can
greatly reduce the severity of the disease caused by the homozy-
gous deletion of SMN1 gene because SMN2 genes, which lack a
splicing enhancer, can generate some functional product, there-
fore can compensate for the loss of the SMN1 gene [98].
2.12. Single nucleotide polymorphism (SNPs) and gene
penetrance
It has long been known that mutations in non coding regions
which affect gene expression can cause human genetic disease.
Classic examples include thalassaemias and hypercholesterol-emia. However the majority of known functional DNA
variants that have been related to disease affect the protein
structure. Currently lists of 26,535 missense/nonsense
mutations compared to 545 regulatory mutations have been
elucidated. This is because their location is generally predict-
able within or around coding sequence and they are easier to
recognise as variants that alter mRNA coding Alternatively,
the discrepancy may be due to regulatory polymorphisms,
having smaller phenotypic effects that in isolation, they are
not sufficient to cause disease [99].
Variation in gene expression occurs and is common in a sub-
stantial proportion of genes. The origin of this variation may be
in allele-specific variation (cis affect), interindividual variation
as a result of polymorphism in other genes that regulates expres-
sion of target genes (trans effect), inter-individual variation in
environmental factors that control gene expression or as a con-
sequence of phenotypic state as drugs and nutrition [99].
SNPs account for 90% of all polymorphisms in humans.
There are about three million SNPs in the human genome (1
per 1000 nucleotides), two thirds of which are in non-coding
DNA [100].
There is a significant association between 381T (rs3815188)
variant and migraine, specifically in migraine without aura
suffers, while the G 684A (rs1043994) variant was found to
be significantly associated with migraine, specifically in
migraine with aura suffers [101].
Frasen et al. [102] select SNPs for follow up that showed a
correlation to gene expression of patients with Crohn’s disease
(CD). They identified two cis expression quantitative trait loci
(cis-e QTL) SNPs that were associated with CD rs2298428 in
UBEL3 and rs2927488 in BCL3.
In long QT syndrome, the genotype of a missense polymor-
phism (lys 897 Thr rs1805123) in KCNH2 gene appears to dis-
tinguish symptomatic from asymptomatic individuals carrying
a low penetrance Ala 116 val pathogenic mutation [103].
Apopulation allele of one SNPmay contribute topathogenes-
es only in the presence of a specific allele of another SNP. These
SNPs may be linked as in the case of migraine susceptibility or
unlinked within different genes as in the transferrin gene [1].
SNPs may also render the pathogenic coding mutation
more or less deleterious or penetrant depending on whether
the allele harbouring it is more or less expressed than the
wild-type allele as in familial hypercholesterolemia [104].
3. To conclude
Some autosomal dominant and autosomal recessive conditions
do not follow the Mendelian genetics. So faithfully, these con-
ditions are said to have incomplete or reduced penetrance.
Reduced penetrance is a common phenomenon in genetic
disorders. It can explain why genetic disorders can occasion-
ally be transmitted through unaffected parents. It also explains
why healthy individuals can have a large number of potentially
disadvantageous mutated variants in their genomes, without
suffering any obvious ill effects.
An estimate of the percentage of penetrance in autosomal
dominant as well as autosomal recessive conditions can be
made from pedigree, family history data and now DNA
sequencing. In fact large population studies are necessary for
measuring penetrance for elucidation of recurrence risks in
genetic counselling.
Reduced penetrance in human inherited disease 109Conflict of interest
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